Dr. Gaston De Serres is an epidemiologist practitioner at the l’Institut national de santé publique du Québec and a regular researcher in the Infectious and Immune Disease Axis at the CHU de Québec-Laval University. He is a full professor in epidemiology in the Department of social and preventive medicine at Laval University where he has been teaching since 1997. He is chief physician of the scientific immunization group (SIG) of the Institut national de santé publique du Québec and an active member of the Comité sur l’immunisation du Québec (CIQ).

Dr. De Serre works on the control and prevention of infectious diseases, with a focus on diseases that are avoidable through vaccination and on respiratory diseases. His research work is on the epidemiology of diseases that are preventable through vaccination and the efficacy of vaccinations used in routine programs, and in particular, on the efficacy of the influenza vaccine.

2400, avenue d'Estimauville, 3e étage
Québec, Québec
Canada G1E 7G9
+1 418-650-5115, extension 6274
+1 418-666-2776
gaston.de-serres@crchudeq... Gaston.DeSerres@inspq.qc....

Latest news

397 entries « ‹ 1 of 40 › »

Dzieciolowska S, Charest H, Roy T, Fafard J, Carazo S, Levade I, Longtin J, Parkes L, Beaulac SN, Villeneuve J, Savard P, Corbeil J, De Serres G, Longtin Y

Timing and Predictors of Loss of Infectivity among Healthcare Workers with Mild Primary and Recurrent COVID-19: a Prospective Observational Cohort Study

Journal Article

Clin Infect Dis, 2023.

Abstract | Links:

Muñoz CE, Pham-Huy A, Pernica JM, Boucher FD, De Serres G, Vaudry W, Constantinescu C, Sadarangani M, Bettinger JA, Tapiéro B, Morris SK, McConnell A, Noya F, Halperin SA, Top KA,

Factors associated with intention for revaccination among patients with adverse events following immunization

Journal Article

Vaccine, 2023.

Abstract | Links:

Zinszer K, Charland K, Pierce L, Saucier A, Hamelin MÈ, Da Torre MB, Carbonneau J, Nguyen CT, De Serres G, Papenburg J, Boivin G, Quach C

Infection-induced seroconversion and seroprevalence of SARS-CoV-2 among a cohort of children and youth in Montreal, Canada

Journal Article

Influenza Other Respir Viruses, 17 (8), 2023.

Abstract | Links:

Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Fafard J, Gilca R, Talbot D, Ouakki M, Febriani Y, Deceuninck G, De Wals P, De Serres G

Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada

Journal Article

Lancet Healthy Longev, 4 (8), 2023.

Abstract | Links:

Zinszer K, Charland K, Pierce L, Saucier A, McKinnon B, Hamelin MÈ, Cheriet I, Da Torre MB, Carbonneau J, Nguyen CT, De Serres G, Papenburg J, Boivin G, Quach C

Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montréal, Canada

Journal Article

Int J Infect Dis, 131 , 2023.

Abstract | Links:

Tauzin A, Benlarbi M, Medjahed H, Grégoire Y, Perreault J, Gendron-Lepage G, Gokool L, Morrisseau C, Arlotto P, Tremblay C, Kaufmann DE, Martel-Laferrière V, Levade I, Côté M, De Serres G, Bazin R, Finzi A

Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination

Journal Article

Vaccines (Basel), 11 (2), 2023.

Abstract | Links:

Skowronski DM, Chuang ES, Sabaiduc S, Kaweski SE, Kim S, Dickinson JA, Olsha R, Gubbay JB, Zelyas N, Charest H, Bastien N, Jassem AN, De Serres G

Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23

Journal Article

Euro Surveill, 28 (5), 2023.

Abstract | Links:

Ionescu IG, Skowronski DM, Sauvageau C, Chuang E, Ouakki M, Kim S, De Serres G

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12-17 Years, by Dosing Interval and Duration

Journal Article

J Infect Dis, 227 (9), 2023.

Abstract | Links:

Tauzin A, Nicolas A, Ding S, Benlarbi M, Medjahed H, Chatterjee D, Dionne K, Gong SY, Gendron-Lepage G, Bo Y, Perreault J, Goyette G, Gokool L, Arlotto P, Morrisseau C, Tremblay C, Martel-Laferrière V, De Serres G, Levade I, Kaufmann DE, Côté M, Bazin R, Finzi A

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine

Journal Article

Cell Rep, 42 (1), 2023.

Abstract | Links:

Bettinger JA, Irvine MA, Shulha HP, Valiquette L, Muller MP, Vanderkooi OG, Kellner JD, Top KA, Sadarangani M, McGeer A, Isenor JE, Marty K, Soe P, De Serres G,

Adverse Events Following Immunization With mRNA and Viral Vector Vaccines in Individuals With Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection From the Canadian National Vaccine Safety Network

Journal Article

Clin Infect Dis, 76 (6), 2023.

Abstract | Links:

397 entries « ‹ 1 of 40 › »
Signaler des ajouts ou des modifications

Active projects

  • (SI03 QC03) Special Immunization Clinic Network (SIC) to investigate vaccine safety issues: Optimizing the clinical management of patients with contraindication to vaccination ..., from 2019-04-01 to 2024-03-31
  • CV07 QC03 Canadian National Vaccine Safety (CANVAS) network: Surveillance of Adverse Events Following Immunization among children and adults Immunized with the COVID-19 Vaccine, from 2021-04-01 to 2023-09-30
  • Enquête sérologique chez les travailleurs de la santé qui rapportent n’avoir jamais fait la COVID-19 depuis le début de la pandémie, from 2023-04-20 to 2023-12-31
  • Fréquence et séquelles fonctionnelles du syndrome post-COVID-19 chez les travailleurs de la santé , from 2023-03-02 to 2025-07-31
  • HPV vaccination effectiveness in a Canadian setting, 12 years after implementation: are we on the road to eliminate cervical, from 2020-10-01 to 2024-09-30
  • SI05 QC03, Optimizing the clinical management of patients with adverse events following COVID-19 vaccination and potential contraindications to vaccination in the Special Immunization Clinic Network, from 2021-11-01 to 2024-03-31
  • SI06 QC03, Optimizing the clinical management of patients with adverse events following COVID-19 vaccination and potential contraindications to vaccination in the Special Immunization Clinic Network, from 2021-04-01 to 2023-10-31
  • The test-negative design for the estimation of COVID-19 vaccine effectiveness: design evaluation and development of statistical methods in the evolving context, from 2022-10-01 to 2025-09-30

Recently finished projects

  • (CV04 QC03) CANVAS Network - Surveillance of adverse events following immunization among children and adults immunized with the influenza vaccine, from 2017-06-01 to 2022-03-31
  • Canadian Immunization Research Network, from 2014-06-01 to 2021-12-31
  • Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) COVID-19 Vaccine Post-Market Studies, from 2020-12-01 to 2023-06-30
  • Efficacité des vaccins contre la CVOID-19, from 2021-04-20 to 2022-06-30
  • Identification de stratégies pour outiller les gestionnaires des milieux de soins pour l’application optimale des mesures de prévention et contrôle des infections chez les travailleurs de la santé durant la pandémie de COVID-19, from 2021-01-01 to 2022-02-08
  • Prize 202203PJT - The test-negative design for the estimation of COVID-19 vaccine effectiveness: design evaluation and development of statistical methods in the evolving context, from 2022-10-01 to 2023-03-31
  • Surveillance des manifestations cliniques survenant après la vaccination contre la COVID-19 au Québec, from 2020-12-01 to 2021-12-31
Data provided by the Université Laval research projects registery